RFL News and Press, Rafael Holdings Inc. Class B From 03/13/25

The planned merger with Cyclo Therapeutics is anticipated to close in Q3 pending shareholder approvals Post-merger the Company intends to focus its efforts on Cyclo’s lead clinical program Trappsol ® Cyclo™ NEWARK, N.J., March 13, 2025 (GLOBE NEWSW...

Portage Biotech Inc. (PRTG) is expected to report for Q3 2025 Aimei Health Technology Co. Ltd (AFJK) is expected to report for quarter end 2024-12-31 Generation Bio Co. (GBIO) is expected to report $-0.28 for Q4 2024 TAT Technologies Ltd. (TATT) is expected to report for quarter end 2...